Navigation Links
Celebrex Plus Lipitor Could Fight Prostate Cancer
Date:4/14/2008

Combining painkiller with statin slows tumor progression, mouse study suggests

MONDAY, April 14 (HealthDay News) -- Two widely used drugs -- one lowers cholesterol and one is an anti-inflammatory -- may be useful in controlling prostate cancer.

New research being presented at the American Association for Cancer Research annual meeting in San Diego finds that the painkiller Celebrex and the statin Lipitor, when used together or alone, can stop early prostate cancer before it becomes deadly.

The study was conducted in mice so the idea isn't yet ready for clinical use, but experts said these preliminary results did look promising.

"They need to come up with the molecular mechanics and then take it back to clinical trials," said Dr. K. Scott Coffield, a professor of surgery at Texas A&M Health Science Center College of Medicine and a urologist-oncologist at Scott & White. "It's early but it's interesting and that's wonderful."

"It's very intriguing and it gives some clinical data, but it's not enough to start recommending these medications for people who don't need them for other reasons," added Dr. Ronald D. Ennis, director of radiation oncology at St. Luke's Roosevelt Hospital, Continuum Cancer Centers, in New York City.

Prostate cancer is the second-leading cancer killer in men in the United States. In the early stages, prostate tumors depend on androgen (male) hormones such as testosterone to grow. As such, early treatment typically involves interfering with these hormones but these therapies eventually lose their effectiveness. Tumors that are dependent on androgen are typically less aggressive than later tumors that don't rely on androgen.

Epidemiological studies have suggested that statins (such as Lipitor) and nonsteroidal anti-inflammatory drugs (such as Celebrex) may be able to stop the progression from an early cancer to a later, more aggressive malignancy.

This study aimed to delay the progression of androgen-dependent tumors to androgen-independent tumors, thus allowing doctors more time to administer anti-hormone therapy. Anti-androgen therapy is less toxic than many other cancer therapies, as are Lipitor and Celebrex.

"Comparing complications for many anti-cancer treatments, these drugs generally would be very safe," Ennis said. (Celebrex, a cox-2 inhibitor, is the only drug in this class still on the market in the United States; two others, Vioxx and Bextra, were withdrawn because of safety issues).

In the study, the investigators first cultured prostate tumors in mice, then added in either Lipitor or Celebrex, and then the combination of the two drugs.

All three approaches inhibited cancer growth. Interestingly, however, the combination of Lipitor and Celebrex at lower doses than when given individually resulted in a greater effect, the team found.

"It had a pretty substantial effect with this combination," said study senior author Allan Conney, director of the Susan Lehman Komen Laboratory for Cancer Research at the Ernest Mario School of Pharmacy of Rutgers University, in New Brunswick, N.J.

"We're hoping that this can be extrapolated to humans," Conney added. "There's a need to do a clinical trial on this combination of Lipitor and Celebrex to see if it can prolong the time that it takes to convert the androgen-dependent tumors to androgen-independent tumors, which are the more severe kind."

As of now, it's unclear why Lipitor and Celebrex are having this effect on prostate tumors.

Ennis doubted it was a cholesterol issue. "Statins as a group must have another effect beyond lowering cholesterol," he said. "They're known to have some anti-inflammatory effects but what they're doing to cancer isn't known yet. Once we figure that out, we may be able to develop better drugs that do the same thing."

"That's very exciting but not yet enough to start prescribing this for prostate cancer," Ennis added.

More information

There's more on prostate cancer at the American Cancer Society.



SOURCES: Allan Conney, Ph.D., Garbe professor, cancer and leukemia research, and director, Susan Lehman Komen Laboratory for Cancer Research, Ernest Mario School of Pharmacy, Rutgers University, New Brunswick, N.J.; Ronald D. Ennis, M.D., director, radiation oncology, St. Luke's Roosevelt Hospital, Continuum Cancer Centers, New York City; K. Scott Coffield, M.D., professor, surgery, Texas A&M Health Science Center College of Medicine and urologist-oncologist, Scott&White


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Celebrex-Lipitor combo may halt prostate cancer
2. Statement of Robert Jarvik, MD, President and CEO of Jarvik Heart, Inc. Regarding the Lipitor DTC Advertisements
3. Study provides hope that some transplant patients could live free of antirejection drugs
4. Study provides hope that some transplant patients could live free of anti-rejection drugs
5. HIV denialists spread misinformation online -- consequences could be deadly; and more
6. Virus Could Help Drive Obesity
7. Discovery of sugar sensor in intestine could benefit diabetes
8. Cranberry Could Juice Up Ovarian Cancer Treatment
9. Treating Diabetes During Pregnancy Could Lead to Thinner Kids
10. High-risk behaviors could lead to HIV epidemic in Afghanistan
11. Chinas 1-child policy could backfire on its elderly
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Celebrex Plus Lipitor Could Fight Prostate Cancer
(Date:2/26/2017)... Italy (PRWEB) , ... February 26, 2017 , ... ... last call for entries to the 7th Edition of International Social Design Awards. ... Social Design Professionals, Product Designers, System Designers, Governments and Institutions worldwide with realized ...
(Date:2/26/2017)... York (PRWEB) , ... February 26, 2017 , ... ... products for wholesale distribution in North America, today announced it would be offering ... The company, which prides itself on crafting quality and unique baby clothing/feeding products, ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ODH, Inc.™ ... Summit, February 27-28 at the Sheraton Pentagon City Hotel in Arlington, VA. ODH’s director ... to use behavioral health analytics to improve Medicaid population health management. , ODH will ...
(Date:2/25/2017)... ... February 25, 2017 , ... FCPX users now have the ability ... Film Studios. With ProSharpen Color users have total control over sharpening amount, sharpening radius, ... range. With color spectrum tools users can visually see the color range effected with ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after ... Travel Market (ILTM) show in Cannes (France), XO Private has initiated a second print-run ... 420-page book measures almost a metre across when open, weighs in at more than ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , February 24, 2017 Following ... Israel , s AMAR is a ... 250 M w ound care market in ... BST for inclusion in the National Health ... system   E-QURE Corp. (OTCQB: EQUR), a ...
(Date:2/24/2017)... -- Research and Markets has announced the addition of the ... 2025" report to their offering. ... The Global Empty Capsules Market is poised to grow at ... $2.9 billion by 2025. This industry report analyzes the ... well as regional levels presented in the research scope. The study provides ...
(Date:2/24/2017)... Pa. , Feb. 24, 2017 Physician ... of Drug and Alcohol Programs Jennifer Smith ... in providing training for and using naloxone, a life-saving ... Mark McCullough , a recovery specialist and overdose survivor ... by EMS providers. "A significant part of ...
Breaking Medicine Technology: